As of close of business last night, CureVac N.V.’s stock clocked out at $3.33, down -1.19% from its previous closing price of $3.37. In other words, the price has decreased by -$0.0400 from its previous closing price. On the day, 1371690 shares were traded.
Ratios:
To gain a deeper understanding of CVAC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.41 and its Current Ratio is at 3.56. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, SVB Securities on June 08, 2023, initiated with a Outperform rating and assigned the stock a target price of $13.
On January 19, 2023, UBS Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $8 to $18.
Jefferies Upgraded its Hold to Buy on January 09, 2023, whereas the target price for the stock was revised from $9 to $21.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CVAC now has a Market Capitalization of 745.67M and an Enterprise Value of 280.75M. For the stock, the TTM Price-to-Sale (P/S) ratio is 16.30 while its Price-to-Book (P/B) ratio in mrq is 1.17. Its current Enterprise Value per Revenue stands at 6.55 whereas that against EBITDA is -1.01.
Stock Price History:
Over the past 52 weeks, CVAC has reached a high of $12.36, while it has fallen to a 52-week low of $3.27. The 50-Day Moving Average of the stock is 3.5836, while the 200-Day Moving Average is calculated to be 6.6013.
Shares Statistics:
It appears that CVAC traded 1.26M shares on average per day over the past three months and 847.25k shares per day over the past ten days. A total of 195.00M shares are outstanding, with a floating share count of 91.60M. Insiders hold about 59.08% of the company’s shares, while institutions hold 10.02% stake in the company. Shares short for CVAC as of Feb 29, 2024 were 4.39M with a Short Ratio of 3.47, compared to 4.14M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.96% and a Short% of Float of 11.06%.
Earnings Estimates
As of right now, 6 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of -$0.2 for the current quarter, with a high estimate of -$0.11 and a low estimate of -$0.34, while EPS last year was -$0.66. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.15 and low estimates of -$0.24.
Analysts are recommending an EPS of between -$0.91 and -$1.21 for the fiscal current year, implying an average EPS of -$1.05. EPS for the following year is -$0.99, with 9 analysts recommending between -$0.55 and -$1.43.
Revenue Estimates
In the current quarter, 7 analysts expect revenue to total $36.87M. It ranges from a high estimate of $78.67M to a low estimate of $20.53M. As of the current estimate, CureVac N.V.’s year-ago sales were $12.83M, an estimated increase of 187.30% from the year-ago figure. For the next quarter, 3 analysts are estimating revenue of $16.4M, an increase of 13.40% less than the figure of $187.30% in the same quarter last year. There is a high estimate of $26.22M for the next quarter, whereas the lowest estimate is $8.77M.
